LifeMD Inc 2024年度报告

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-K For the fiscal year ended December 31, 2024 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesտNoց Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days. YesցNoտ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesցNoտ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. Large accelerated filerտNon-accelerated filerտEmerging growth companyտ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.տ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.ց Indicate by check mark whether the financial statements included in the filing reflects a correction of an error to previously issued financial statements: YesտNoտ Indicate by check mark whether any of those error corrections are restatements requiring a recovery analysis of incentive-based compensation under the registrant’sclawback policies: YesտNoտ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesտNoց The aggregate market value of the common stock held by non-affiliates of the registrant as of June 28, 2024 was $242,784,078 as computed by reference to the closingprice of such common stock on such date. The registrant had 44,583,688 shares of common stock outstanding as of March 7, 2025. DOCUMENTS INCORPORATED BY REFERENCE Portions of the 2025 definitive proxy statement for the Registrant’s Annual Meeting of Stockholders, to be filed within 120days of our fiscal year end (December 31,2024) are incorporated by reference into Part III of this Form 10-K. LIFEMD, INC.2024 FORM 10-K ANNUAL REPORTTABLE OF CONTENTS PART I ITEM 1. BUSINESS........................................................................................................................................................5ITEM 1A. RISK FACTORS............................................................................................................................................14ITEM 1B. UNRESOLVED STAFF COMMENTS .........................................................................................................35ITEM 1C. CYBERSECURITY .......................................................................................................................................35ITEM 2. PROPERTIES ...................................................................................................................................................36ITEM 3. LEGAL PROCEEDINGS .................................................................................................................................36ITEM 4. MINE SAFETY DISCLOSURES.....................................................................................................................36 PART II ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, ANDISSUER PURCHASES OF EQUITY SECURITIES ......................................................................................................37ITEM 6. RESERVED ......................................................................................................................................................37ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATIONS ..........................................................................................................................................................37ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK...............................43ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA...........................................................